- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07944118
Examination of How the Duration of Fasting and Temporary Stopping of Zenagamtide Dosing Affect the Amount of Food Left in the Stomach in Adults With Overweight or Obesity, With or Without Type 2 Diabetes
Investigation of the Effect of Fasting Duration and Temporary Withholding of Subcutaneous Administration of Zenagamtide on Retained Gastric Contents in Participants With Overweight or Obesity, With or Without Type 2 Diabetes
The purpose of this clinical study is to find out how the duration of fasting (not eating or drinking, except for water) and pausing of treatment with zenagamtide medication affect the amount of food and liquid left in the stomach of people using zenagamtide.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 1
Contactos e Locais
Contato de estudo
- Nome: Novo Nordisk
- Número de telefone: (+1) 866-867-7178
- E-mail: clinicaltrials@novonordisk.com
Locais de estudo
-
-
California
-
Cypress, California, Estados Unidos, 90630
- Altasciences Clinical LA, Inc.
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Male or female (sex assigned at birth, inclusive of all gender identities).
- Age 18 and older at the time of signing the informed consent.
- Considered eligible based on the medical history, physical examination, and the results of vital signs, electrocardiogram (ECG) and clinical laboratory tests performed during the screening visit, as judged by the investigator.
For participants with type 2 diabetes (T2D)
- Diagnosed with type 2 diabetes (T2D) more than (>) 180 days before screening.
- No treatment with oral anti-diabetic drugs except metformin. Treatment with metformin should be stable (dose and dosing frequency) for at least 90 days before screening.
Exclusion Criteria:
- Known or suspected hypersensitivity to study intervention(s) or related products.
- Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using adequate contraceptive method.
- Presence of clinically significant gastrointestinal disorders or symptoms of gastrointestinal disorders as judged by the investigator.
- Diagnosed with or suspected to suffer from gastroparesis, hiatal hernia or severe gastro-oesophageal reflux diseases with daily symptoms and/or when in supine position.
- Use of other medications known to affect the motility of the stomach.
- Inability to lie in the right lateral decubitus position for gastric ultrasonography.
For participants without T2D - Glycated haemoglobin (HbA1c) more than or equal to (≥) 6.5 percent (%) [48 millimoles per mole (mmol/mol)] at screening.
For participants with T2D
- HbA1c ≥ 10.5 % (91 mmol/mol) at screening.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Zenagamtide
Participants will receive zenagamtide once weekly subcutaneously (s.c.). |
Zenagamtide will be administered subcutaneously using PDS290 pre-filled pen-injectors in one of the body parts: thigh, abdomen or upper arm. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Occurrence of empty stomach (antrum grade 0 or 1) after fasting following a solid, high-fat meal 1 day after dosing of s.c. zenagamtide once weekly (Yes/No)
Prazo: 6, 8, 10, 12, 18 and 24 hours after start of fasting on visit 2 day 1 (V2D-1) and V19D2
|
Measured as count of participants |
6, 8, 10, 12, 18 and 24 hours after start of fasting on visit 2 day 1 (V2D-1) and V19D2
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Occurrence of empty stomach (antrum grade 0 or 1) after fasting following a liquid meal 1 day after dosing of s.c. zenagamtide once weekly (Yes/No)
Prazo: 6, 8, 10, 12, 18 and 24 hours after start of fasting on V2D-4 and V17D2
|
Measured as count of participants |
6, 8, 10, 12, 18 and 24 hours after start of fasting on V2D-4 and V17D2
|
|
Gastric volume after fasting following a liquid meal 1 day after dosing of s.c. zenagamtide once weekly
Prazo: 6, 8, 10, 12, 18 and 24 hours after start of fasting on V2D-4 and V17D2
|
Measured as milliliter per kilogram (mL/kg) |
6, 8, 10, 12, 18 and 24 hours after start of fasting on V2D-4 and V17D2
|
|
Gastric volume after fasting following a solid, high-fat meal 1 day after dosing of s.c. zenagamtide once weekly
Prazo: 6, 8, 10, 12, 18 and 24 hours after start of fasting on V2D-1 and V19D2
|
Measured as mL/kg |
6, 8, 10, 12, 18 and 24 hours after start of fasting on V2D-1 and V19D2
|
|
Presence of solids in the stomach (antrum grade 'solid') after fasting following a liquid meal 1 day after dosing of s.c. zenagamtide once weekly (Yes/No)
Prazo: 6, 8, 10, 12, 18 and 24 hours after start of fasting on V2D-4 and V17D2
|
Measured as count of participants |
6, 8, 10, 12, 18 and 24 hours after start of fasting on V2D-4 and V17D2
|
|
Presence of solids in the stomach (antrum grade 'solid') after fasting following a solid, high-fat meal 1 day after dosing of s.c. zenagamtide once weekly (Yes/No)
Prazo: 6, 8, 10, 12, 18 and 24 hours after start of fasting on V2D-1 and V19D2
|
Measured as count of participants |
6, 8, 10, 12, 18 and 24 hours after start of fasting on V2D-1 and V19D2
|
|
Occurrence of empty stomach (antrum grade 0 or 1) after fasting following a solid, high-fat meal 4 days after dosing of s.c. zenagamtide once weekly (Yes/No)
Prazo: 6, 8, 10, 12, 18 and 24 hours after start of fasting on V19D5
|
Measured as count of participants |
6, 8, 10, 12, 18 and 24 hours after start of fasting on V19D5
|
|
Gastric volume after fasting following a solid, high-fat meal 4 days after dosing of s.c. zenagamtide once weekly
Prazo: 6, 8, 10, 12, 18 and 24 hours after start of fasting on V19D5
|
Measured as mL/kg |
6, 8, 10, 12, 18 and 24 hours after start of fasting on V19D5
|
|
Presence of solids in the stomach (antrum grade 'solid') after fasting following a solid, high-fat meal 4 days after dosing of s.c. zenagamtide once weekly (Yes/No)
Prazo: 6, 8, 10, 12, 18 and 24 hours after start of fasting on V19D5
|
Measured as count of participants |
6, 8, 10, 12, 18 and 24 hours after start of fasting on V19D5
|
|
Occurrence of empty stomach (antrum grade 0 or 1) after fasting following a solid, high-fat meal 7 days after dosing of s.c. zenagamtide once weekly (Yes/No)
Prazo: 6, 8, 10, 12, 18 and 24 hours after start of fasting on V19D8
|
Measured as count of participants |
6, 8, 10, 12, 18 and 24 hours after start of fasting on V19D8
|
|
Gastric volume after fasting following a solid, high-fat meal 7 days after dosing of s.c. zenagamtide once weekly
Prazo: 6, 8, 10, 12, 18 and 24 hours after start of fasting on V19D8
|
Measured as mL/kg |
6, 8, 10, 12, 18 and 24 hours after start of fasting on V19D8
|
|
Presence of solids in the stomach (antrum grade 'solid') after fasting following a solid, high-fat meal 7 days after dosing of s.c. zenagamtide once weekly (Yes/No)
Prazo: 6, 8, 10, 12, 18 and 24 hours after start of fasting on V19D8
|
Measured as count of participants |
6, 8, 10, 12, 18 and 24 hours after start of fasting on V19D8
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Diretor de estudo: Clinical Transparency (dept. 2834), Novo Nordisk A/S
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Doenças do Sistema Endócrino
- Distúrbios Nutricionais
- Doenças Metabólicas
- Supernutrição
- Peso corporal
- Distúrbios do Metabolismo da Glicose
- Diabetes Mellitus
- Condições Patológicas, Sinais e Sintomas
- Doenças Nutricionais e Metabólicas
- Sinais e sintomas
- Excesso de peso
- Obesidade
- Diabetes Mellitus, Tipo 2
Outros números de identificação do estudo
- NN9490-8698
- U1111-1336-6870 (Outro identificador: World Health Organization (WHO))
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .